glp 1 pharmacology Non-insulin injectable antidiabetic drugs - GLP-1 agonists and amylinomimetics Current Insights, Advantages and Challenges

Clinical evidence: key trials and outcomes The kidney-protective potential of SGLT2 inhibitors was first identified in cardiovascular outcome trials, including Empagliflozin Cardiovascular Outcome Event Trial in Type 2 Diabetes Mellitus PatientsRemoving Excess Glucose (EMPA-REG OUTCOME) [36], Canagliflozin Cardiovascular Assessment Study (CANVAS) [37], and Dapagliflozin Effect on Cardiovascular EventsThrombolysis in Myocardial Infarction 58 (DECLARETIMI 58) [38]

Unreconstituted lyophilized powder can be stored at room temperature for short periods or in the refrigerator/freezer for extended shelf life

Know how to convert

doi: 10.1016/j.nutres.2015.12.017 31